Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection

Transplantation

Volumn 69, Issue 11, 2000, Pages 2405-2409

  Ojo, Akinlolu O ^a   Meier Kriesche, Herwig Ulf ^a   Hanson, Julie A ^a   Leichtman, Alan B ^a   Cibrik, Diane ^a   Magee, John C ^a   Wolfe, Robert A ^a   Agodoa, Lawrence Y ^b   Kaplan, Bruce ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SURVIVAL RATE; UNITED STATES;

EID: 0034660104     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006150-00033     Document Type: Article

References (25)

1. Paul LC. Chronic renal transplant loss. Kidney Int 1995; 47: 1491.
2. Kasiske BL. Clinical correlates to chronic renal allograft rejection. Kidney Int Suppl 1997; 63: S71.
3. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783.
4. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167.
5. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group [see comments]. Lancet 1995; 345: 1321.
6. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group [see comments]. Transplantation 1996; 61: 1029.
7. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group. Transplant Proc 1997; 29: 348.
8. Mycophenolate Mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999; 68: 391.
9. Mycophenolate Mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis 1999; 34: 296.
10. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1216.
11. Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. Transplant Proc 1997; 29: 304.
12. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
13. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van BC. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040.
14. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110.
15. Abramowicz D. Daclizumab to prevent acute rejection in renal transplantation [letter; comment]. N Engl J Med 1998; 338: 1700.
16. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group [see comments]. N Engl J Med 1998; 338: 161.
17. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999; 67: 276.
18. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group [published erratum appears in Lancet 1997 Nov 15;350(9089):1484], Lancet 1997; 350: 1193.
19. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583.
20. Fujihara CK, Malheiros DM, Zatz R, Noronha ID. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510.
21. Muller V, Hamar P, Szabo A, Knust E, Vogelsang M, Heemann U. Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. Transplant Proc 1998; 30: 982.
22. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999; 10: 1542.
23. Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160.
24. Sollinger HW. From mice to man: the preclinical history of mycophenolate Mofetil. Clin Transplant 1996; 10: 85.
25. Weir MR, Anderson L, Fink JC, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706.